Chronic Myeloid Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
Finding ways to stop cancer at its roots

Finding ways to stop cancer at its roots

Leukemia drug appears to be effective in treating deadly pediatric brain tumor

Leukemia drug appears to be effective in treating deadly pediatric brain tumor

Leukemia is not just one disease

Leukemia is not just one disease

Disparities in race, ethnicity, and status affect progress in cancer survival rates in youth

Disparities in race, ethnicity, and status affect progress in cancer survival rates in youth

Study shows how SIRT1 plays key role in maintaining the regenerative potential of leukemic stem cells

Study shows how SIRT1 plays key role in maintaining the regenerative potential of leukemic stem cells

Chemistry researchers patent new method for making anti-leukemia compounds

Chemistry researchers patent new method for making anti-leukemia compounds

Bio-Rad launches new digital PCR system and kit for monitoring treatment response in CML patients

Bio-Rad launches new digital PCR system and kit for monitoring treatment response in CML patients

Physicians more likely to prescribe drugs of manufacturers who paid them money

Physicians more likely to prescribe drugs of manufacturers who paid them money

Potential combination therapy against rare disease of the bone marrow could improve treatment

Potential combination therapy against rare disease of the bone marrow could improve treatment

Research highlights ability of Bio-Rad's ddPCR in quantifying minimal residual disease

Research highlights ability of Bio-Rad's ddPCR in quantifying minimal residual disease

Using molecular targeting approach to kill melanoma cells

Using molecular targeting approach to kill melanoma cells

Drug combination targets pre-leukemia stem cells

Drug combination targets pre-leukemia stem cells

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science

OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science

Study: Single surface protein can amplify multiple key pathways in acute myeloid leukemia

Study: Single surface protein can amplify multiple key pathways in acute myeloid leukemia

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Researchers test new cancer research model that may reduce cost and speed up studies

Researchers test new cancer research model that may reduce cost and speed up studies

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Study finds link between industry payments and prescription practices for two cancer types

Study finds link between industry payments and prescription practices for two cancer types

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.